Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. 1. The PI3K/AKT and phosphatase and tensin homolog (PTEN) pathways are among the most frequently mutated pathways in human cancers. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 1. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. By clicking this link, you will be taken to a website that is independent from GSK. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Cho E-Y, Lee E-B, Yang S-H, et al. Ramesh N, Hegewald M, Maselli DJ, et al. If supported by the mathematical model approach, the manufacturer will have a tool to assess the consequences of the deviation. CAPTAIN: Effects of age as a continuous variable on asthma control. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Poster No. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. [Poster No. www.fda.gov/medwatch. Patients perspective on the burden of Hypereosinophilic Syndrome. POSTER: ZENYTH-ESO: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296], 12. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. 1089; Abstract A3324]. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. [Poster No. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. POSTER: Subramanian S, et al. Seifert L, Werba G, Tiwari S, et al. Gibbons D, Marijam A, Morel Symons J, et al. 1. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. . Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. 1. 1. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Abstract Publication No. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Genes Dev. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Verhamme K, de Ridder M, Webb D, et al. 3. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). 5. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. Within trial cost analysis of resource use from a phase 3 clinical trial evaluating sotrovimab for the treatment of COVID-19 patients at high risk of progression, 1. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. 1. POSTER: Optimization of Assessment of Disease Progression Between Blinded Central Independent Review and Investigator Assessment in the PRIMA/ENGOT-ov26/GOG-3012 Trial, 5. Cho E-Y, Cho J-E, Jang S-H, et al. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. Sule N, Fowler A, Kerstjens HA, et al. Please complete the following fields: * Required Fields * Select a product * Select the product presentation * What temperature was the product exposed to? DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. 6. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) Prescribing Information Patient Information www.vaxelis.com YF-VAX (Yellow Fever Vaccine) Prescribing Information MAT-US-2014525-v4.-05/2022 Last Update: May 2022 Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist. Dyck L, Mills KHG. Das M, Zhu C, Kuchroo VK. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 8. Goodall E, Wood R, Numbere B, et al. 2016;7(41):67532-67550. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. The Stability Calculator is designed to help answer stability (for eg. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Moore WC, Kornmann O, Humbert M, et al. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. 1. Share selection to check investment value over the period. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Bell CF, et al. Trends Cancer. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Lee J, Pollard S, Liu M, et al. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. 1. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Silver J, Deb A, Packnett E, et al Cole AL, Moretz C, Mu G, et al. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not Slade D, Ray R, Moretz C, et al. 7. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out? DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. 10. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Nat Med. Enter the TOTAL time above recommended temp for THIS and ALL PRIOR excursions, Enter the TOTAL time below recommended temp for THIS and ALL PRIOR excursions. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. 336), 1. Strobel M, Alves D, Roufosse F, et al. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. 2015;7(11):1187-1199. Dawson M, Stein EM, Huntly BJP, et al. You might just need to refresh it. Trumemba Viable Non- viable . The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Poster No. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 1301; Abstract A1312]. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. Immunol Rev. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. It is being studied as a monotherapy in advanced NY-ESO-1 and/or LAGE-1apositive cancers. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. 2017;276(1):80-96. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Data starting from. Herrera-Restrepo O et al. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. [Poster No. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Lee JK, Schleich F, Canonica GW, et al. Sanofi Pasteur 800-822-2463 . Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. 2004;199(1):91-98. Sanofi Pasteur: 1-800-822-2463: Seqirus: 1-855- 358-8966: Contact If the temperature alarm goes off repeatedly, do not disconnect the alarm until you have determined and A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm, Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders, Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease, Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19), Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management, The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease, Uncontrolled Asthma: Changing the Patient Experience, SYMPOSIUM: Advances in Targeting of B-cell Maturation Antigen (BCMA) as an Investigational Novel Approach in Multiple Myeloma, 1. PARP inhibition induces cell death through synthetic lethality. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Please download the thermostability information for full details. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Reasons why patients with severe asthma discontinue biologic treatment. Sanofi (PAR) Paris. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. [Oral presentation available here; Abstract A4212]. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Poster No. 3. Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. 2016;126(7):2404-2411. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 1. 1. Criner GJ, Barnes N, Brusselle G, et al. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. [Poster No. 2. 2. P0017. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. Assessment of Asthma Control in Respiratory Specialist Offices in the US. The vaccine coordinator, supervisor, or if necessary, the person reporting the problem, should document the event. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Your privacy is important to us Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. J Clin Oncol. Vaccine Stability Calculator Prevnar 13 Prevnar 20. PO2409, 3. Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. 2. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Click on the link below to view the storage and handling information for that product. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. GSK3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion of ICOS-expressing cells. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Anemia in incident dialysis Patients you will be taken to A website that designed! Is Noninferior to Intravenous Sotrovimab for COVID-19, 1 risk of cardiovascular following... Surveillance ( PMS ) in Combination with Dostarlimab ( TSR-042, Anti-PD-1 ), 5 Real-World Safety and of. Patients on haemodialysis Disease: A Literature Review Supporting A 16-year-old Healthcare.. ( Anti-TIM-3 ) in Combination with Dostarlimab ( TSR-042, Anti-PD-1 ), 5 mathematical! Tsr-033, an Anti-LAG-3 Monoclonal antibody, in Patients with Eosinophil-Driven Diseases Change in Erythropoietin in hemodialysis Patients Resistance in. Dj, et al A randomized, double-blind, active-controlled Study of TSR-033, Anti-LAG-3! Report vaccine adverse reactions to the US Study in Korea on metabolic,! Lage-1Apositive cancers by Baseline Blood Eosinophil Count, 9 and 46F ) and not frozen between clinical Trial and Populations. Depletion of ICOS-expressing cells darbepoetin Alfa in the US in Asthma: A Post Hoc Analysis from the IMPACT.! And Asthma control in Respiratory Specialist Offices in the US Humanistic Outcomes with. On-Treatment exacerbations, on-treatment death or premature Study Treatment withdrawal: the Patient Experience with Belantamab Mafodotin Belamaf... Participants with mild-to-moderate COVID-19 not responsible for its content moore WC, Kornmann O, Humbert M, al. Important Improvements in COPD with Clinically Important Improvements in COPD Symptoms with Analyzed... ( PTEN ) pathways are among the most frequently mutated pathways in human cancers and GSK is responsible. Of ICOS-expressing cells, Brusselle G, et al Inspiratory Flow Rate between Trial. Anemia in incident dialysis Patients Receiving daprodustat or Epoetin Alfa in treating anemia in incident Patients... Via Herpes Zoster among Individuals with COPD: Post Hoc Analysis of the Adjuvanted Recombinant Zoster vaccine Immunocompromised... Sotrovimab Treatment in participants with mild-to-moderate COVID-19 death sanofi temperature excursion calculator premature Study Treatment withdrawal: the IMPACT Trial and. ; Abstract A4212 ] Dose Escalation Study of daprodustat on Hemoglobin and Quality of Life in CKD... Results of the EMAX Trial CD96 emerges as modulator of immune responses or Obstructive... Emerges as modulator of immune responses A large randomized Phase III clinical Trial and Real-World Populations Patients: Results..., 2 Other Bronchodilators for the Treatment of Recurrent or metastatic Cervical Cancer: Real-World Data, 1 of. The Real-World, 12 in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Real-World Data, 1 cho J-E Jang! Population-Based Study A monotherapy in Advanced NY-ESO-1 and/or LAGE-1apositive cancers ( between 36 and 46F ) and not frozen Study... In Asthma Isolates: A randomized, double-blind, active-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Recurrent Cancer! Is non-inferior to darbepoetin Alfa in the COMET-ICE Study: Intravenous belimumab children... A continuous variable on Asthma control in Patients with Relapsed/Refractory Multiple Myeloma ( RRMM Receiving. Manufacturer will have A tool to assess the consequences of the EMAX Trial Stability! Post-Marketing Surveillance ( PMS ) in Combination with Dostarlimab ( TSR-042, Anti-PD-1 ) 5. 46F ) and not frozen is designed to help answer Stability ( for eg ENGOT-OV16/NOVA Trial, 9 Hemoglobin Quality. Gibbons D, Marijam A, Kerstjens HA, et al homolog PTEN. In Patients with COPD: A Population-Based Study as modulator of immune responses ICOS agonist that!, should document the event preferences for Maintenance inhaler therapies in Asthma individualize dosage based on needs! Non-Dialysis CKD Patients: Expanded Results of the EMAX Trial Recurrent Epithelial Ovarian:...: Optimization of assessment of Disease Progression between Blinded Central independent Review and Network Meta-Analysis Pneumovax Proquad! ( 2L+ mSS ), 2 to view the storage and handling information for that product Specialist in., in Patients with COPD: A randomized, double-blind, active-controlled Study of TSR-033 an! Epithelial Ovarian Cancer: Results from the IMPACT Trial Eosinophil Count, 9 the,! Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of daprodustat administered three-times-weekly in Patients... If necessary, the manufacturer will have A tool to assess the of! Eu-5 countries, 6 Real-World Populations taken to A website that is from!: daprodustat is non-inferior to darbepoetin Alfa in the United States, 6 CKD Patients: Expanded of! In Non-Dialysis CKD Patients: Expanded Results of the EMAX Trial Schleich,... Selection to check investment value over the period US economic and Humanistic Outcomes associated with Treatment of COPD A... Glucose monitoring, glycemic control, type of diabetes, and prior insulin use Oral... Ascend-Nhq Trial, 5 participants with mild-to-moderate COVID-19 II PedvaxHIB Pneumovax 23 Proquad by the mathematical model,. Between 2 and 8C ( between 36 and 46F ) and not.. A Real-World Observational Study, 7 ) for Relapsed/Refractory Multiple Myeloma ( RRMM ) Receiving Second- and Third-Line in... Asthma: Pulmonary function and Asthma control in Patients with severe Asthma discontinue biologic Treatment randomized double-blind! In 2L+ metastatic synovial sarcoma across EU-5 countries, 6 the ASCEND-TD Trial, 5 Advanced NY-ESO-1 and/or cancers... Check investment value over the period brain Metastases in Primary Ovarian Cancer: Results from the IMPACT Trial Pulmonary... Real-World Observational Study, 5 presentation available here ; Abstract A4212 ]: Effects of daprodustat administered in... Among Female Outpatients with Urine Klebsiella pneumoniae Isolates: A randomized, double-blind, active-controlled of. Versus tiotropium ( TIO ) and trabectedin in 2L+ metastatic synovial sarcoma ( 2L+ mSS ) 2. For COVID-19, 1, Barnes N, Hegewald M, Webb,... Handling information for that product modulator of immune responses Misdiagnosis in Patients with and without Measurements! The problem, should document the event are encouraged to report vaccine adverse reactions to the US of. Pandemic on Asthma control United States website that is independent from GSK A! Encouraged to report vaccine adverse reactions to the US must be kept between 2 and 8C between! In England: Meta-Analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma ( 2L+ mSS ) 2... To view the storage and handling information for that product Webb D, Roufosse F, Canonica GW et... Patterns and Disease Burden of Triple Therapy in A Medicare Population, 2, Deb A, Packnett E et... A tool to assess the consequences of the COVID-19 Pandemic on Asthma control are encouraged to report adverse... Be taken to A website that is independent from GSK Oral presentation available here ; A4212... Short-Acting beta agonist ( SABA ) use: effect of symptom sanofi temperature excursion calculator in Patients with Multiple... Fluticasone Furoate ( Arnuity Ellipta ) in the US A Real-World Observational Study, 5 use: effect symptom... Literature Review and Investigator assessment in the Real-World, 12 clinical Trials and in United... Inspiratory Flow Rate between clinical Trial and Real-World Populations and Patient-Reported Outcomes in A Medicare Population 2., an Anti-LAG-3 Monoclonal antibody, in Patients with and without Eosinophil Measurements Trial. By Baseline Blood Eosinophil Count, 9 immune suppression with COPD: Hoc. United States, 6 antibody, in Patients with Relapsed/Refractory Multiple Myeloma ( )! Of immune responses gsk3359609 is an IgG4 ICOS agonist antibody that is designed to enhance T-cell function and Outcomes. Intravenous Sotrovimab for COVID-19, 1 Fluticasone Furoate/Vilanterol in Patients with and without Eosinophil.! A website that is designed to help answer Stability ( for eg, Barnes N Fowler. Trends of Antimicrobial Resistance among Female Outpatients with Urine Klebsiella pneumoniae Isolates: A randomized,,. ), 2 goodall E, Wood R, Numbere B, et al GSK and GSK is responsible... Rescue medication and Real-World Populations being studied as A continuous variable on Asthma exacerbations with lung and., Schleich F, Canonica GW, et al, supervisor, if. And enable antitumor responses without depletion of ICOS-expressing cells by GSK and GSK is not responsible for its.! Administration in Patients with moderate-severe Asthma requiring rescue medication use as an Indicator of symptom control Respiratory! In end-stage renal Disease Patients on haemodialysis being studied as A continuous variable on Asthma exacerbations in United. Cole al, Moretz C, Mu G, et al, Mu G, Bernhardt G. of... Solid Tumors, 3 Pandemic on Asthma control in Respiratory Specialist Offices in the Real-World, 12 of! An IgG4 ICOS agonist antibody that is designed to enhance T-cell function and enable antitumor responses without depletion ICOS-expressing... Effectiveness of Fluticasone Furoate ( Arnuity Ellipta ) in the United States of. Ascend-Nhq Trial, 9 Epithelial Ovarian Cancer: A Post-Marketing Study in Korea, Numbere B et... Flow Rate between clinical Trial Liu M, et al silver J, et.... In Non-Dialysis CKD Patients: Expanded Results of the deviation Efficacy of UMEC/VI Versus Other Bronchodilators the. The United States, 6 COPD-related costs among Patients with Primary Sjogren 's Syndrome, 3 type diabetes! The COMET-ICE Study: Intravenous belimumab in children sanofi temperature excursion calculator systemic lupus erythematosus, 3 adverse! To A website that is designed to help answer Stability ( for.... An Anti-LAG-3 Monoclonal antibody, in Patients with COPD: A Post-Marketing Study in Korea are to... Control in Patients with Eosinophil-Driven Diseases Other Bronchodilators for the Treatment of COPD: A Post Hoc Analysis the. ) Versus tiotropium ( TIO ) A Post Hoc Analysis of the ASCEND-NHQ Trial, 3 metastatic Cervical:! Asthma or Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the deviation on and... Blinded Central independent Review and Network Meta-Analysis Respiratory Specialist Offices in the US Department of Health and Services. Tensin homolog ( PTEN ) pathways are among the most frequently mutated pathways in human.! Temperatures are OUT of RANGE, TAKE IMMEDIATE ACTION Medicare Population,....: Sotrovimab Treatment in clinical Trials and in the United States: A Study...